Advertisement
Versamune(TM)-HPV is an immunotherapy drug which has demonstratedsignificant promise in curing HPV infection and HPV-related cancer inpreclinical animal and human model studies. Cancers caused by infection withthe human papilloma virus (HPV) include cervical, head and neck and analcancers. No cures exist for these cancers. Based on promising in vivo and invitro efficacy data, PDS Biotechnology Corporation was awarded in August 2008,a phase I SBIR grant by the US National Institutes of Health/National CancerInstitute to develop Versamune(TM)-Melanoma to treat melanoma, which is themost aggressive form of skin cancer.
Advertisement
PDS Biotechnology Corporation's Versamune(TM) nanotechnology facilitatesthe uptake of disease-associated protein and peptide antigens by the antigen-presenting cells of the immune system and simultaneously acts a strong immunesystem activator (adjuvant) without the inflammatory side effects induced bycurrent adjuvants. The result is simple, safe and cost effectivenanotechnology-based drugs and vaccines that induce effective eradication ofthe specific cells infected with, or expressing the particular proteinformulated with Versamune(TM).
PDS Biotechnology Corporation (www.pdsbiotech.com) is a Cincinnati,Ohio-based biotechnology company applying the company's proprietaryVersamune(TM) nanotechnology drug platform technology to the development ofsafe and potent immunotherapies to prevent and to treat cancer and diseasescaused by infectious agents.
The NCL is a formal collaboration between the US National CancerInstitute, the US Food and Drug Administration (FDA) and the NationalInstitute of Standards and Technologies (NIST) to rapidly advance promisingcancer nanotechnology drugs through regulatory submissions with the FDA.
SOURCE PDS Biotechnology Corporation
